- Home
- CHRS vs MRCC Comparison
CHRS vs MRCC Comparison
Compare CHRS & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- MRCC
- Stock Information
- Founded
- CHRS 2010
- MRCC 2011
- Country
- CHRS United States
- MRCC United States
- Employees
- CHRS N/A
- MRCC N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- MRCC Investment Managers
- Sector
- CHRS Health Care
- MRCC Finance
- Exchange
- CHRS Nasdaq
- MRCC Nasdaq
- Market Cap
- CHRS 84.2M
- MRCC 176.4M
- IPO Year
- CHRS 2014
- MRCC 2012
- Fundamental
- Price
- CHRS $0.82
- MRCC $6.46
- Analyst Decision
- CHRS Buy
- MRCC Hold
- Analyst Count
- CHRS 3
- MRCC 1
- Target Price
- CHRS $4.68
- MRCC $8.00
- AVG Volume (30 Days)
- CHRS 1.3M
- MRCC 91.8K
- Earning Date
- CHRS 08-07-2025
- MRCC 08-06-2025
- Dividend Yield
- CHRS N/A
- MRCC 15.48%
- EPS Growth
- CHRS N/A
- MRCC 3301.50
- EPS
- CHRS N/A
- MRCC 0.32
- Revenue
- CHRS $272,251,000.00
- MRCC $56,983,000.00
- Revenue This Year
- CHRS N/A
- MRCC N/A
- Revenue Next Year
- CHRS $106.56
- MRCC N/A
- P/E Ratio
- CHRS $1.87
- MRCC $19.88
- Revenue Growth
- CHRS 19.87
- MRCC N/A
- 52 Week Low
- CHRS $0.66
- MRCC $6.11
- 52 Week High
- CHRS $2.43
- MRCC $8.85
- Technical
- Relative Strength Index (RSI)
- CHRS 53.13
- MRCC 50.70
- Support Level
- CHRS $0.72
- MRCC $6.19
- Resistance Level
- CHRS $0.77
- MRCC $6.65
- Average True Range (ATR)
- CHRS 0.04
- MRCC 0.15
- MACD
- CHRS 0.01
- MRCC 0.02
- Stochastic Oscillator
- CHRS 91.62
- MRCC 50.88
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.